

Day 1: Sunday, 25 November 2012

0900 – 1600 **REGISTRATION**

1430 – 1605 **SCIENTIFIC SESSION 1:
PRE-CONFERENCE SYMPOSIUM ON NUCLEAR CARDIOLOGY** Auditorium, Ground Floor

Session Chairpersons:

1. Dr Pankaj Dougall, Nuclear Medicine and PET-CT, Max Super Speciality Hospitals, New Delhi, India
2. Dr Kok Tian Yue, Nuclear Medicine and PET, Singapore General Hospital, Singapore

1430 – 1455 **Myocardial Viability – Implications for Clinicians**
PC-1
Dr Carlos D Libhaber, Nuclear Medicine, University of the Witwatersrand, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

1455 – 1520 **Role of Radionuclide Imaging in Heart Failure**
PC-2
Prof Zuo-Xiang He, Nuclear Medicine, Fu Wai Hospital & Cardiovascular Institute, Beijing, China

1520 – 1540 **New Experimental Tracers for Myocardial Ischemia**
PC-3
Prof Henry Bom, Nuclear Medicine, Chonnam National University Hospital, Jeonnam, Korea

1540 – 1605 **Assessment of Cardiac Dyssynchrony: A Nuclear Approach**
PC-4
Prof Chetan Patel, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India

1605 – 1630 **COFFEE / TEA / TRADE EXHIBITION**

1630 – 1830 **SCIENTIFIC SESSION 2:
PRE-CONFERENCE SYMPOSIUM ON ARCTIC ENVIRONMENT** Auditorium, Ground Floor

Session Chairpersons:

1. Prof Mauri Yla-Kotola, University of Lapland, Finland
2. Prof Kalevi Kairemo, Molecular Radiotherapy & Nuclear Medicine, International Comprehensive Cancer Center Docrates, Helsinki, Finland

1630 – 1655 **Hospitals, Hospitality and Hosting Health – An Arctic Avenue**
PC-5
Prof Johan Edelman, Multidimensional Tourism Institute, University of Lapland, Rovaniemi, Finland

1655 – 1705 **Human Thermal Responses During Reindeer Safaris in Cold**
PC-6
Dr Susanna Paakkola, Arctic Centre, University of Lapland, Rovaniemi, Finland

1705 – 1730 **Northern Lights Through the Eyes of a Space Scientist**
PC-7
Prof Thomas Ulich, Director, Sodankyla Geophysical Observatory, University of Oulu, Oulu, Finland

1730 – 1745 **Glaciological Research in Svalbard**
PC-8
Dr Martina Schafer, Arctic Centre, University of Lapland, Rovaniemi, Finland

1745 – 1805 **Arctic Sculptures, Snow & Ice**
PC-9
Prof Timo Jokela, University of Lapland, Rovaniemi, Finland

1805 – 1830 **Many Faces of Love**
PC-10
Prof Kaarina Maatta, University of Lapland, Rovaniemi, Finland

1830 – 1930 **WARMTH GOVERNING BODY MEETING
(GOVERNING BODY MEMBERS ONLY)** To be Advised

1930 – 2200 **WELCOME DINNER** Restaurant Okta, Ground Floor
Hotel Levi Panorama

2200 **END OF DAY 1**

Day 2: Monday, 26 November 2012

0800 – 1600 **REGISTRATION**

0830 – 0900 **SCIENTIFIC SESSION 3: OPENING**

Auditorium, Ground Floor

Welcome

Prof Kalevi Kairemo, Local Organising Chairman, ICRT 2012

Opening Remarks

Prof Ajit Kumar Padhy, International Organising Chairman, ICRT 2012 & President-WARMTH

WARMTH Candle Lighting Ceremony

Prof Harvey Turner, Prof Ajit Kumar Padhy, Prof Richard P Baum, Prof Alan Perkins, Prof Kalevi Kairemo & Other Members of WARMTH Governing Body

0900 – 1100 **SCIENTIFIC SESSION 4: THYROID DISEASES I**

Auditorium, Ground Floor

Session Chairpersons:

1. **Prof Mike Sathekge, Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa**
2. **Prof Ralph McCready, Nuclear Medicine, Royal Sussex County Hospital, Brighton, United Kingdom**

0900 – 0920 **Subclinical Hyperthyroidism – To Treat or Not to Treat with Radioiodine**

S-1

A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland

0920 – 0940 **Graves' Ophthalmopathy & Radioiodine Therapy**

S-2

Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines

0940 – 1000 **Thyroid Cancer and Nuclear Accident**

S-3

Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan

1000 – 1020 **Use of Rh-TSH (Thyrogen) in Thyroid Cancer – A Review**

S-4

Dr Sze Ting Lee, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia

1020 – 1040 **Modern Imaging in Detection of Iodine Negative-Tg Positive Differentiated Thyroid Cancer**

S-5

Prof Jasna Mihailovic, Nuclear Medicine, Oncology Institute of Vojvodina, Novi Sad, Serbia

ORAL PRESENTATIONS

Auditorium, Ground Floor

1040 – 1050 **Efficacy of Different Protocols of Radioiodine Therapy for Treatment of Toxic Nodular Goiter: Systematic Review and Meta-Analysis of the Literature**

O-1

Dr R Zakavi, et al (Iran)

1050 – 1100 **Early Radioiodine Ablation Post Thyroidectomy with Recombinant TSH (r-TSH) Stimulation and its Impact on Performance Status, Versus Thyroxine Abstinence Protocol in Differentiated Thyroid Carcinoma : Initial Results of a Randomized Prospective Clinical Trial**

O-2

Dr P Choudhary, et al (India)

1100 – 1130 **COFFEE / TEA / TRADE EXHIBITION**

1100 – 1130 **POSTER PRESENTATIONS**

Session Coordinators:

1. **Dr Ruben Ogbac, Nuclear Medicine, St Luke's Medical Center, Quezon City, Philippines**
2. **Dr Erdenechimeg Seregotov, Nuclear Medicine, First Central Hospital, Ulaanbaatar, Mongolia**

P-1

What is the Alternative to Radioiodine Therapy in Diffuse Pulmonary Metastasis from Papillary Thyroid Carcinoma in Children

Dr Kaouther Chatti, et al (Tunisia)

P-2

Thyroid Cancer Treated at the Clinical Center Banja Luka. A Review of 5 Years Experience

Dr Zvezdana Rajkovic, et al (Serbia)

P-3

Optimization of 90Y-antiCD20 Preparation for Radioimmunotherapy

Dr Amir R Jalilian, et al (Iran)

P-4

Optimized Preparation of [64Cu]-DOTA-Trastuzumab for PET Applications

Dr Amir R Jalilian, et al (Iran)

Day 2: Monday, 26 November 2012

| | |
|------|---|
| P-5 | Significance of Post-Therapy SPECT-CT Scan in Differentiated Thyroid Cancer Dr Rajesh Kumar, et al (India) |
| P-6 | Patient's Specific Dosimetry for Radioiodine Therapy of Thyroid Cancer and Comparison with Fixed Doses Dr Noreen Marwat, et al (Pakistan) |
| P-7 | Bone Metastases from Differentiated Thyroid Carcinoma: Clinical Features and Long Term Follow Up Dr Nurun Nahar, et al (Bangladesh) |
| P-8 | Salivary Gland Tumor After Radioiodine Therapy for Well Differentiated Thyroid Carcinoma: A Case Report Prof Lutfun Nisa, et al (Bangladesh) |
| P-9 | Radioactive Iodine Ablation in Children and Adolescents with Differentiated Thyroid Carcinoma Dr Yustia Tuti Jelani, et al (Indonesia) |
| P-10 | The Advantages of Routine Radiothyroablation in Well Differentiated Thyroid Carcinoma Patients Dr Hapsari Indrawati, et al (Indonesia) |
| P-11 | Clinical Outcome of Differentiated Thyroid Carcinoma with Lymph Node Metastasis : A Retrospective Analysis of Patients Treated at a Single Institute Dr Faria Nasreen, et al (Bangladesh) |
| P-12 | Papillary Thyroid Carcinoma after Maximum Radioiodine Therapy with Persistent Disease (A Case Study) Dr Ryna Z Martiana, et al (Indonesia) |
| P-13 | Clinical Behavior of Follicular Variant of Papillary Thyroid Carcinoma at INMU Dr Sadia Sultana, et al (Bangladesh) |
| P-14 | Detection and Treatment of Lung Metastases in Differentiated Thyroid Carcinoma Dr Zeenat Jabin, et al (Bangladesh) |
| P-15 | Clinical Significance of Thyroglobulin Antibody Pattern in Patients with Differentiated Thyroid Carcinoma: Preliminary Study Dr Ivana Dewi Mulyanto, et al (Indonesia) |
| P-16 | Two Cases with Unusual Uptake in the Whole Body Scan with Radioiodine 131: Textiloma; Miliary Tuberculosis Dr Ben Rais Aouad Nozha, et al (Moroco) |
| P-17 | A Rare Pediatric Case of Metastatic Papillary Thyroid Carcinoma in the Brain Dr Karina Michaela Dela Cruz, et al (Philippines) |
| P-18 | Diagnostic Difficulty Due to Incidental Fibrous Dysplasia in a Patient with Metastatic Follicular Thyroid Cancer and the Possible Association of these Entities with McCune Albright Syndrome Dr Sumbul Zaheer, et al (Singapore) |
| P-19 | The Value of PET/CT in the Diagnosis and Therapy of Thyroid Cancer Dr Emerita Barrenechea, et al (Philippines) |
| P-20 | Radioiodine Treatment for Thyrotoxicosis in Childhood and Adolescence: Treatment and Outcome Dr Sirianong Namwongprom, et al (Thailand) |
| P-21 | Follow-up of High Risk Thyroid Cancer Patients with Bone and Lung Metastases Dr Rosanna Morales, et al (Peru) |
| P-22 | Low Dose Radioiodine Ablation for Differentiated Thyroid Carcinoma (DTC) - A Retrospective Analysis Dr Damayanthi KK Nanayakkara, et al (Sri Lanka) |
| P-23 | Clinical Outcome of Radioactive Iodine Therapy Among Patients with Hyperthyroidism in St. Luke's Medical Center-Philippines Dr Irene Bandong, et al (Philippines) |
| P-24 | Hürthle Cell Carcinoma – The Nuclear Medicine Specialist Point of View Dr Ana Ugrinska, et al (Macedonia) |
| P-25 | Role of Thyroglobulin (Tg) Level and Whole-Body Scan (WBS) After I-131 Therapy in Patients with Differentiated Thyroid Cancer Dr Shankar Biswas, et al (Bangladesh) |
| P-26 | Potential Response of Grave's Disease Associated with Thymic Hyperplasia After Radioactive Iodine 131 Therapy: A Case Report Dr Bonan A. Mendoza, et al (Philippines) |
| P-85 | Experience with 30 mCi Iodine-131 Ablation Therapy for DTC in Sarawak General Hospital Dr Dahlia Saidin, et al (Malaysia) |

Day 2: MONDAY, 26 November 2012

| | | |
|---|---|--|
| 1130 – 1305 | SCIENTIFIC SESSION 5: BONES & JOINTS / METASTATIC BONE PAIN PALLIATION | Auditorium, Ground Floor |
| Session Chairpersons: 1. Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel 2. Dr Sze Ting Lee, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia | | |
| 1130 – 1150 S-10 | Intermittent Pneumatic Compression: Effect on MDP Uptake – A Potential Method to Facilitate Therapy Prof Abdelhamid Elgazzar, Medical Faculty, University of Kuwait, Safat, Kuwait | |
| 1150 – 1210 S-11 | Radionuclide Imaging of Bone Metastases: Science & Practice Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom | |
| 1210 – 1225 S-60 | Radiosynovectomy-Procedure Review and Description of A Multicentre Study to Measure the Safety and Efficacy of Radiosynovectomy Performed with Y-90 Citrate Colloid and Re-186 Sulfide Dr James Warrington, Nuclear Medicine, London Health Sciences Centre, London, Canada | |
| 1225 – 1245 S-12 | Radiosynovectomy in the Treatment of Arthritis Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany | |
| 1245 – 1305 S-19 | Assessing Tuberculosis Response to Therapy Prof Mike Sathekge, Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa | |
| 1305 – 1400 | LUNCH / TRADE EXHIBITION | Restaurant Okta, Ground Floor Hotel Levi Panorama |
| 1400 – 1613 | SCIENTIFIC SESSION 6: THYROID DISEASES II | Auditorium, Ground Floor |
| Session Chairpersons: 1. Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany 2. Dr Achmad Hussein Sundawa Kartamihardja, Nuclear Medicine, Dr Hasan Sadikin General Hospital, Bandung, Indonesia | | |
| 1400 – 1425 S-7 | Clinical Role of F-18 FDG PET/CT for Differentiated Thyroid Cancer Before and After High Dose I-131 Therapy Prof Henry Bom, Nuclear Medicine, Chonnam National University Hospital, Jeonnam, Korea | |
| 1425 – 1445 S-8 | Role of SPECT-CT in Diagnosis, Staging and Follow Up of Patients with Thyroid Diseases Dr Sonya Sergieva, Nuclear Medicine, Sofia Cancer Center, Sofia, Bulgaria | |
| 1445 – 1500 S-9 | Management of Differentiated Thyroid Cancer: A Single Centre Experience & Lessons Learnt in the Last 20 Years Dr Shazia Fatima, Nuclear Medicine, Nuclear Medicine, Oncology & Radiotherapy Institute, Islamabad, Pakistan | |
| 1500 – 1525 S-6 | Therapeutic Approaches in Thyroid Cancer – What is Next to Standard Treatment? Dr Daniel Putzer, Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria | |
| ORAL PRESENTATIONS | | Auditorium, Ground Floor |
| 1525 – 1533 O-3 | Clinical Significance of Measurement of Serum Anti Thyroglobulin Antibodies (ATgAb) in the Follow Up of Differentiated Thyroid Carcinoma Dr Javid Irfan, et al (Pakistan) | |
| 1533 – 1541 O-4 | Consequences of Misadministration in Handling of Radiopharmaceuticals Prof Ajai Kumar Shukla (India) | |
| 1541 – 1549 O-5 | Experience with 177Lu-EDTMP Regarding Improvement in Quality of life and Bone Pain Palliation Dr Ghazal Jameel, et al (Pakistan) | |
| 1549 – 1557 O-6 | Hydroxyapatite Particles Labelled with Beta-Emitting Lanthanoids for Radiosynovectomy Dr Mohammad Sohaib, et al (Pakistan) | |
| 1557 – 1605 O-7 | The Pilot Study To Evaluate the Effectiveness of Radiosynoviorthesis (RSO) of Sacro-iliac Joints with Re-186 Dr Marika Vereb, et al (Germany) | |
| 1605 – 1613 O-8 | Radiation synovectomy with Yttrium (90Y) Citrate in rheumatoid arthritis patients- 5 years of follow up Dr Ljiljana Jaukovic, et al (Serbia) | |
| 1613 – 1630 | COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION | |

Day 2: MONDAY, 26 November 2012
1613 – 1630 POSTER PRESENTATIONS
Session Coordinators:

1. Dr Ana Ugrinska, Institute of Pathophysiology and Nuclear Medicine, Skopje, Macedonia
2. Dr Anne Poksi, Nuclear Medicine Centre, East-Tallinn Central Hospital, Tallinn, Estonia

- | | |
|------|---|
| P-27 | Effectiveness of Radiation Synovectomy with Yttrium (90Y) Citrate Related to Preexisting Radiological Damage in Rheumatoid Arthritis Patients Dr Boris Ajdinovic, et al (Serbia) |
| P-28 | Treatment Efficacy of Sm-153 Lexidronate for Pain Management of Bone Metastases: The First Experience in Iran Dr Narjess-Khatoun Ayati, et al (Iran) |
| P-29 | Clinical Characteristics, Efficacy of I-131 Therapy and Outcome of Patients with Differentiated Thyroid Cancer having Bone Metastases – A Retrospective Study Dr Sadaf Butt, et al (Pakistan) |
| P-30 | Production, Quality Control and Biological Evaluation of 153Sm-isoPDTMP and 153Sm-TTHMP as a Possible Bone Palliation Agent Dr Zohreh Naseri, et al (Iran) |
| P-31 | Effectiveness of Strontium -89 Therapy in Multiple Bony Metastases Patient with CA. Breast and CA.Prostate Dr Om Prakash Sinha, et al (India) |
| P-32 | A Study on Strontium-90 Irradiation for Treatment of Post-Operative Conjunctival Squamous Cell Carcinoma Prof Raihan Hussain, et al (Bangladesh) |
| P-33 | The Synthesis, Radiolabeling and First Biological Evaluation of a New 166Ho-Complex for Radiotherapy of Bone Metastases Dr Samaneh Zolghadri, et al (Iran) |
| P-34 | Post- Therapy Precautions and Imaging Properties of Samarium 53 vs Strontium-89 Mr Rey Martin Jr Goco, et al (Philippines) |
| P-35 | Semi-Quantitative Estimation of Samarium-153 Oxabifore Therapy Results of Metastatic Bone Disease in Mono - Regime and in Combination with Bisphosphonates Dr Nigora Rasulova, et al (Uzbekistan) |
| P-36 | Preparation and Biodistribution of 99mTc and 188Re Labeled Zoledronic Acid Dr Olga Klementyeva, et al (Russia) |
| P-37 | Radiopharmaceutical Based on Monopotassium Salt of Hydroxyethylendiphosphonic Acid Labeled with 188Re for Therapy of Bone Metastases Dr Vasily Petriev, et al (Russia) |
| P-38 | Potential Role of Semi-Quantitative Analyses of Bone Metastases in Evaluation of Radionuclide Therapy Response Dr Nigora Rasulova, et al (Uzbekistan) |

Day 2: MONDAY, 26 November 2012

| | | |
|--|--|--------------------------|
| 1630 – 1830 | SCIENTIFIC SESSION 7: MOLECULAR IMAGING & RADIONUCLIDE THERAPY | Auditorium, Ground Floor |
| Session Chairpersons: 1. Dr Michael Tomblyn, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA 2. Dr William Macdonald, Nuclear Medicine, Royal Perth Hospital, Perth, Australia | | |
| 1630 – 1650 S-14 | Potentially required number of PET apparatus in Asia and Latin America including Mexico Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan | |
| 1650 – 1710 S-15 | Treatment Response Evaluation using current imaging modalities Prof Rakesh Kumar, Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India | |
| 1710 – 1730 S-16 | Avibodies – A Novel Approach for Targeting Prostate and Ovarian Cancer Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia | |
| 1730 – 1750 S-17 | Percutaneous Radionuclide Therapy (PERTH) Prof Ralph McCready, Nuclear Medicine, Royal Sussex County Hospital, Brighton, United Kingdom | |
| 1750 – 1810 S-18 | Current Status of PET Radiopharmaceuticals in PET/CT Guided Radiotherapy Treatment Planning Dr Antonija Balenovic, PET/CT Center, Poliklinika Medikol, Zagreb, Croatia | |
| 1810 – 1830 S-13 | Development of New Radiopharmaceuticals for Diagnosis and Treatment of Arthritis Prof Vijay Kumar, Nuclear Medicine & PET, Westmead Hospital, Sydney, Australia | |
| 1930 – 2300 | FORMAL INAUGURAL CEREMONY | Restaurant Taivas |
| <ul style="list-style-type: none"> ▪ WARMTH Awards ▪ Dinner (More Details To Follow) | | |
| 2300 | END OF DAY 2 | |

Day 3: TUESDAY, 27 November 2012

| | | |
|---------------------|--|--------------------------|
| 0810 – 0930 | SCIENTIFIC SESSION 8: WARMTH: HISTORY, FUTURE PERSPECTIVES & INTERNATIONAL COLLABORATIONS | Auditorium, Ground Floor |
| | Session Chairpersons: 1. Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia 2. Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA | |
| 0810 – 0830 S-20 | History of WARMTH Prof Ajit Kumar Paddy, Nuclear Medicine & PET, Singapore General Hospital, Singapore | |
| 0830 – 0850 S-21 | IAEA Perspectives on Radionuclide Therapy Prof Adriano Duatti, Nuclear Applications, IAEA, Vienna, Austria | |
| 0850 – 0910 S-22 | WFNMB Perspectives on Radionuclide Therapy Prof Andrew Scott, President Elect, WFNMB (2014-2018), Australia | |
| 0910 – 0930 S-23 | Future Prospects of Radionuclide Therapy in Korea Prof Dong Soo Lee, Nuclear Medicine, Seoul National University Hospital, Seoul, Korea | |
| 0930 – 1105 | SCIENTIFIC SESSION 9: NEURO-ENDOCRINE TUMORS I | Auditorium, Ground Floor |
| | Session Chairpersons: 1. A/Prof Grzegorz Kaminski, Endocrinology & Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland 2. Dr Vikram Lele, Director, Nuclear Medicine, Jaslok Hospital & Research Centre, Mumbai, India | |
| 0930 – 0955 S-24 | Personalized Radionuclide Therapy of Cancer – Will It Remain a Dream or Become Reality? Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany | |
| 0955 – 1020 S-25 | Innsbruck Medical University: Long-term Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria | |
| 1020 – 1045 S-26 | NETs: Labeled Somatostatin Analogues in Therapy Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy | |
| 1045 – 1105 S-27 | Clinical Trial Evaluation of Radiopeptide Therapy of Neuroendocrine Tumours Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia | |
| 1105 – 1130 | COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION | |
| 1105 – 1130 | POSTER PRESENTATIONS | |
| | Session Coordinators: 1. Dr Marika Vereb, Nuklearmedizin, Klinikum Kassel, Kassel, Germany 2. Dr Masha Maharaj, Nuclear Medicine, Polokwane Provincial Hospital, University of Limpopo, Pietersburg, South Africa | |
| P-39 | Selective Internal Radiation Therapy using Yttrium-90 Microspheres: A Practical Demonstration of Personalised Artery Specific Dosimetric Modeling Ms Toh Ying, et al (Singapore) | |
| P-40 | Production and Quality Control of [166 Ho]-DOTA-Bevacizumab for Therapeutic Applications Dr Alireza Khorrani, et al (Iran) | |
| P-41 | Assessment of Human Effective Absorbed Dose of 67Ga-ECC Based on Biodistribution Rat Data Dr Hassan Yousefina, et al (Iran) | |
| P-42 | Radiation Safety Consideration in 90Y- Microsphere Therapy Dr Ashish Jha, et al (India) | |
| P-43 | SPECT/CT & PET/CT in Imaging Neuroendocrine Tumours: Pearls and Patterns Dr Sadia Salam, et al (Bangladesh) | |
| P-44 | Fast Preparation of 131I-MIBG for Therapy Purposes in Nuclear Medicine Dr Ali Sattari, et al (Iran) | |
| P-45 | Ga-68 DOTATATE PET/CT in Tumour-Induced Osteomalacia Dr Ammad Al Tamimi, et al (Singapore) | |

Day 3: TUESDAY, 27 November 2012

| | |
|---|---|
| P-46 | Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Progressive Neuroendocrine Neoplasms Dr Harshad Kulkarni, et al (India) |
| P-47 | Role of Ga-68 Somatostatin Receptor PET/CT in the Determination of Molecular Response to Radiofrequency Ablation of Hepatic Metastases from Neuroendocrine Neoplasms Dr Harshad Kulkarni, et al (India) |
| P-48 | Believe it or Not! Renal Function can Actually Improve after Peptide Receptor Radionuclide Therapy Dr Harshad Kulkarni, et al (India) |
| 1130 – 1200 | SCIENTIFIC SESSION 10: NEURO-ENDOCRINE TUMORS II / LYMPHOMA Auditorium, Ground Floor |
| Session Chairpersons: | |
| 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany | |
| 2. Prof Bozena Birkenfeld, Nuclear Medicine, Uni Lubelskiej, Szczecin, Poland | |
| 1130 – 1150 S-28 | An Update on PRRT in India Dr Vikram Lele, Nuclear Medicine, Jaslok Hospital & Research Centre, Mumbai, India |
| 1150 – 1210 S-29 | Somatostatin Analogs as Possible Theragnostic Molecules for Advanced Prostate Cancer Prof Omar Alonso, Nuclear Medicine, Clinical Hospital, University of Uruguay, Montevideo, Uruguay |
| 1210 – 1230 S-30 | Phase II Study of First-Line Iodine-131-Rituximab Radioimmunotherapy of Follicular Non-Hodgkin Lymphoma: The INITIAL Study Dr William Macdonald, Nuclear Medicine, Royal Perth Hospital, Perth, Australia |
| 1230 – 1250 S-31 | Low-Dose, Involved Field Radiotherapy Just Prior to Radioimmunotherapy for Relapsed/Refractory B-Cell Lymphoma Dr Michael Tomblyn, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA |
| 1250 – 1310 S-32 | Radioimmunotherapy (RIT) of Follicular Non Hodgkin's Lymphoma (FNHL). The State of the Art Prof Izak Garty, Nuclear Medicine, Central Emek Hospital, Afula, Israel |
| 1310 – 1400 | LUNCH / TRADE EXHIBITION Restaurant Okta, Ground Floor Hotel Levi Panorama |
| 1400 – 1540 | SCIENTIFIC SESSION 11: DOSIMETRY / RADIOPHARMACY Auditorium, Ground Floor |
| Session Chairpersons: | |
| 1. Prof Frank Roesch, Institute of Nuclear Chemistry, University of Mainz, Mainz, Germany | |
| 2. Prof Vijay Kumar, Nuclear Medicine & PET, Westmead Hospital, Sydney, Australia | |
| 1400 – 1420 S-3 | Paving the Way to Personalized Medicine for Treatment of Cancer and Inflammatory Disorder Dr Suresh Srivastava, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA |
| 1420 – 1430 S-61 | Tin-117m-DOTA-Annexin for Imaging and Treating Vulnerable Plaque Dr Gilbert Gonzales, Collider-Accelerator Department, Brookhaven National Laboratory, New York, USA |
| 1430 - 1440 | What it takes to Build a Radiopharmaceutical Product in the Age of Dwindling Financial support Dr. Immanuel Thangaraj, Essex Woodlands Health Ventures (EWHV), USA |
| 1440 – 1500 S-34 | Personalized Image-Based Dosimetry for Radionuclide Therapies Prof Anna Celler, Radiology, UBC, VGH Research Pavilion, Vancouver, Canada |
| 1500 – 1520 S-35 | A New Approach of Individual Dosimetry Dr Matthias Blaickner, Health & Environment Department, Biomedical Systems, AIT Austrian Institute of Technology, Vienna, Austria |
| 1520 – 1540 S-36 | New Options to Label Biomolecules with Trivalent Radiometals Adding Non-Aqueous Solvents Prof Frank Roesch, Institute of Nuclear Chemistry, University of Mainz, Mainz, Germany |

Day 3: TUESDAY, 27 November 2012

1540 – 1600 COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION

1540 - 1600 POSTER PRESENTATIONS

- | | |
|------|--|
| P-49 | Evaluation and Calculation of Human Absorbed Dose of Tl(III)-201F -DTPA-HlgG based on Biodistribution Data in Rats Dr Alireza Khorrani, et al (Iran) |
| P-50 | Assessment of Human Effective Absorbed Dose of 111In–DTPA–Buserelin Based on Biodistribution Rat Data Dr A Lahooti, et al (Iran) |
| P-51 | Biodistribution of an Ultra Small Super Paramagnetic Iron Oxide Nano Particles in Balb/c Mice Dr Saeed Shanehsazzadeh, et al (Iran) |
| P-52 | Development of a Radiolabeled Glucagon for SPECT Imaging Ms Mahdokht Jouiaei, et al (Iran) |
| P-53 | Biological and Dosimetry Studies of Four Radiolabeled of Rituximab for Human Based on Distribution Data in Rats Dr Edalat Radfar, et al (Iran) |
| P-54 | Investigating the Effectiveness of Low Dose and High Dose Radioiodine Ablation for Post Surgical Thyroid Remnants in Patients with Differentiated Thyroid Carcinoma at Kuala Lumpur Hospital Dr Nor Salita Ali, et al (Malaysia) |
| P-55 | Evaluation and Dosimetry Studies of Human Absorbed Dose of Various Age Groups of 90Y-DOTA-Cetuximab Based on Distribution Data in Rats Dr Ariandokht Vakili, et al (Iran) |
| P-56 | Development of Ho-166 Chitosan for Hepatocellular Carcinoma Dr Hassan Yousefnia, et al (Iran) |
| P-57 | Development and Characterization of Clinical-Grade 64Cu-DOTA-Trastuzumab for HER2/Neu Oncology Imaging Using Dual Head SPECT Dr. Behrooz Alirezapour, et al (Iran) |
| P-58 | In-Vitro and In-Vivo Evaluations of a Novel Potential Folate Receptor Imaging Agent Dr. Esmail Mollarazi, et al (Iran) |
| P-59 | Synthesis, Quality control, Biological Evaluation by a Kinetic Model of [90Y]-DOTA-Cetuximab for Radioimmunotherapy Purpose Dr Ariandokht Vakili, et al (Iran) |
| P-60 | Development of a New In-111 Quinolone Complex as a Possible Imaging Agent Dr Yousef Fazaeli, et al (Iran) |
| P-61 | Development of In-111 and Ga-67 Maltolate Complexes as Imaging Agents Dr Yousef Fazaeli, et al (Iran) |
| P-62 | Synthesis, Radiolabeling and Biological Evaluation of a New 111Indium-Porphyrin Complex as an Imaging Agent Dr Yousef Fazaeli, et al (Iran) |
| P-63 | Synthesis, Characterization and Biological Evaluation of a new 131Iodo porphyrin complex as an imaging agent Dr Yousef Fazaeli, et al (Iran) |
| P-64 | Synthesis, labeling optimization and Biological Evaluation of 111Indium 5,10,15,20-Tetrakis (3,5-di Hydroxyphenyl) Porphyrin Complex as an Imaging Agent Dr Yousef Fazaeli, et al (Iran) |
| P-65 | Our Experience in the Safe and efficient delivery of Radionuclide Therapy for Neuroendocrine Tumors with Lu-177 DOAT-TATE Mr S Somanesan, et al (Singapore) |
| P-66 | Preparation and Quality Control of Lutetium-177 Bleomycin as a Possible Therapeutic Agent Dr Hassan Yousefnia, et al (Iran) |
| P-67 | Development of [177Lu]-Tetra Phenyl Porphyrin Complexes as Possible Imaging Agents Dr Hassan Yousefnia, et al (Iran) |

Day 3: TUESDAY, 27 November 2012

| | | |
|---------------------|---|--------------------------|
| 1600 – 1740 | SCIENTIFIC SESSION 12: DEVELOPMENTS IN THERAPEUTIC RADIOPHARMACEUTICALS | Auditorium, Ground Floor |
| | Session Chairpersons: | |
| | 1. Prof Alan Perkins, Radiological & Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom | |
| | 2. Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria | |
| 1600 – 1620 S-38 | Nanostructures and Their Multiplex Labeling with Targeting Ligands and Radioisotopes Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea | |
| 1620 – 1640 S-39 | Prospects of Lu-177/Y-90 Production and Future Radionuclide Therapy in Korea Dr Sun-Ju Choi, Director, Radioisotope Research Division, Korea Atomic Energy Research Institute, Daejeon, Korea | |
| 1640 – 1700 S-40 | Experience of Platform Construction and Clinical Trial of New Radionuclide Therapy in Korea Dr Gi Jeong Cheon, Nuclear Medicine, Korea University, Seoul, Korea | |
| 1700 – 1720 S-41 | Introducing the Animal Models for Evaluation of New or/and Already Existing Radiopharmaceuticals Prof Emilija Janevik-Ivanovska, University "Goce delcev", Faculty of Medical Sciences, Stip, Republic of Macedonia | |
| 1720 – 1740 S-37 | Review of Available and Future Radionuclides Useful for Radiotherapeutics: Industrial and Regulatory Limitations Dr Richard Zimmermann, Chrysalium Consulting, France | |
| 1740 – 1815 | SCIENTIFIC SESSION 13: RADIONUCLIDE THERAPY QUIZ | Auditorium, Ground Floor |
| | Session Chair & Moderator: | |
| | 1. Dr Gopinath Gnanasegaran, Nuclear Medicine, Guy's & St Thomas Hospital NHS Foundation Trust, London, United Kingdom | |
| 1815 – 1900 | WARMTH MEMBERS' ASSEMBLY ALL MEMBERS OF WARMTH TO ATTEND THE MEETING | Auditorium, Ground Floor |
| 1900 | END OF DAY 3 | |
| 1900 | FREE EVENING (Participants to plan their own activities) | |

Day 4: Wednesday, 28 November 2012

| | | |
|--|--|--------------------------|
| 0800 – 0910 | SCIENTIFIC SESSION 14: ALPHA THERAPY | Auditorium, Ground Floor |
| Session Chairpersons: 1. Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany 2. Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan | | |
| 0800 – 0825 S-42 | Radium-223 (Alpharadin) in The Treatment Of Skeletal Metastases in Prostate Cancer Patients Prof Øyvind S Bruland, Onclogy, University of Oslo, Norwegian Radium Hospital, Oslo, Norway | |
| 0825 – 0850 S-43 | Glioblastoma Therapy with Substance P labelled with Bismuth-213 – Initial Experience Prof Leszek Króllicki, Dr Jolanta Kunikowska, Dr Henryk Koziara, Dr Alfred Morgenstern, F Bruchertseifer, Maciej Jakuciński, Dr Dariusz Pawlak, Dr Renata Mikołajczak, Dr Bartosz Króllicki and Dr Sławomir Barszcz Nuclear Medicine Department, Medical University of Warsaw, POLAND; European Commission, Joint Research Centre, Institute for Transuranium Elements; Institute of Oncology, Maria Skłodowska-Curie Memorial Cancer Center, Warsaw Branch, Warsaw, Poland; Nuclear Medicine Department Brodnowski Hospital, Warsaw, Poland; National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock-Świerk Poland (To be presented by Dr Jolanta Kunikowska) | |
| ORAL PRESENTATIONS | | Auditorium, Ground Floor |
| 0850 – 0900 O-9 | Cis-Diamminedichloroplatinum (II) Enhancement of Antitumor Effect of In-111-Labeled N-Myc Antisense Oligonucleotides in Nude Mouse-Grown Human Neuroblastoma Prof Naoyuki Watanabe, Radiological Sciences, Gunma Prefectural College of Human Health, Maebashi, Japan | |
| 0900 – 0910 O-10 | Ki67 or/and 18FDG PET/CT? Which Do We Need for Qualification Patients to Peptide Receptor Radionuclide Therapy (PRRT) ? Dr Jolanta Kunikowska, Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland | |
| 0910 – 1100 | SCIENTIFIC SESSION 15: BREAST CANCER & MISCELLANEOUS | Auditorium, Ground Floor |
| Session Chairpersons: 1. Dr Gregory Wiseman, Mayo Clinic, Minnesota, USA 2. Dr Nei Wen Long, Radiation Oncology, National Cancer Centre Singapore, Singapore | | |
| 0910 – 0935 S-44 | Contribution of Nuclear Medicine in Early Breast Cancer: From Sentinel Node to IART® (Intra-Operative Avidination For Radionuclide Therapy) Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy | |
| 0935 – 0955 S-45 | Positron Emission Mammography (PEM): A Perspective Dr Patricia Bernal, Nuclear Medicine, Fundacion Santa Fe de Bogota, Bogota, Colombia | |
| 0955 – 1020 S-62 | Oncolytic Viral Therapy Prof Akseli Hemminki, University of Helsinki / Docrates Cancer Center, Finland | |
| 1020 – 1040 S-46 | Statistics – Interesting and Useful Prof Janez Stare, Biostatistics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia | |
| 1040 – 1100 S-47 | Role of Nuclear Medicine in Oncological Surgery Prof Bozena Birkenfeld, Nuclear Medicine, Uni Lubelskiej, Szczecin, Poland | |
| 1100 – 1130 | COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION/ POSTER VIEWING | |

Day 4: Wednesday, 28 November 2012

POSTER PRESENTATIONS

Session Coordinators:

1. **Dr Butch Magsombol**, Nuclear Medicine & PET, Singapore General Hospital, Singapore.
2. **Dr Lucia Kaliska**, Nuclear Medicine, Institute of Nuclear Medicine & Molecular Medicine, Banska Bystrica, Slovakia

| | |
|------|---|
| P-68 | Role of PET/CT in Initial Staging of Lung Cancer Dr Xuan Canh Nguyen, et al (Vietnam) |
| P-69 | Pleuroperitoneal Communication Detected by Technetium 99m-tagged Macroaggregated Albumin (MAA) Radionuclide Peritoneal Scintigraphy in a Chronic Kidney Disease Patient on Peritoneal Dialysis: A Case Report Ms Carla Mari Macaisa , et al (Philippines) |
| P-70 | Significant Impact of a Single End of Treatment F-18 FDG PET/CT Study as a Prognostic Indicator and Predictor of Final outcome in Non-Metastatic Squamous Cell Carcinoma of Head and Neck Region Dr Partha Choudhury, et al (India) |
| P-71 | SPECT-CT for the Diagnosis of Primary Hyperparathyroidism Dr Marina Garcheva, et al (Bulgaria) |
| P-72 | Variations of Gates' GFR Among Different Work Stations Mr Rey Martin Jr Goco (Philippines) |
| P-73 | Measurement of Non-Uniformity in Gamma Cameras: Effect of Crystal Hydration Dr Milena Dimcheva, et al (Bulgaria) |
| P-74 | Correlation of Wall Motion Score and Left Ventricular Ejection Fraction by Gated SPECT Myocardial Perfusion Imaging Prof Raihan Hussain, et al (Bangladesh) |
| P-75 | PET/CT & SPECT/CT in Imaging Prostate Cancer: Tracers, Advantages & Limitations Dr Sadia Salam, et al (Bangladesh) |
| P-76 | Clinical Interest of Hybrid Imaging in Lung Cancer Prof Ben Rais Aouad Nozha, et al (Morocco) |
| P-77 | The Clinical Impact of 18-F Flurocholine PET/CT in the Management of Prostate Cancer Dr Anbalagan Kannivelu, et al (Singapore) |
| P-78 | The Role of Sentinel Lymph Node Biopsy in the Prediction of Metastatic Spread of Malignant Melanoma Dr Anca Zamfirescu, et al (Romania) |
| P-79 | Role of Contrast Enhanced 18F- FDG PET- CT in Restaging of Pancreatic Carcinoma Dr Arun Gandhi, et al (India) |
| P-80 | Controversy over Dense Breast Imaging: Are We Using All the Armaments in Our Arsenal; A Review of Molecular Breast Imaging's Potential Role in the Battle Against Breast Cancer Dr S Krishna Kumar, et al (Singapore) |
| P-81 | Site Specific Radioiodination of HER2-Targeting Affibody Molecules Using Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity Strand J, Nordeman P, Honarvar H, Altai M, Larhed M, Orlova A, Tolmachev V Uppsala University, Uppsala, Sweden |
| P-82 | Is PET and PET/CT useful in Pediatrics? De Leon D, Dr Emerita Barrenechea (Philippines) |
| P-83 | Developing a Nuclear Medicine Outreach Program. The Polokwane Experience Dr Masha Maharaj (South Africa) |
| P-84 | Tc-99m MIBI Scan in Multiple Myeloma Dr Raluca Mititelu, et al (Romania) |

Day 4: Wednesday, 28 November 2012

| | | |
|---|--|--|
| 1130 – 1310 | SCIENTIFIC SESSION 16: LIVER AND GI CANCER | Auditorium, Ground Floor |
| Session Chairpersons: 1. Dr Patricia Bernal, Nuclear Medicine, Fundacion Santa Fe de Bogota, Bogota, Colombia 2. Prof Jae Min Jeong, Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea | | |
| 1130 – 1150 S-48 | Clinical use of Rhenium-188 from the Tungsten-188/Rhenium-188 Generator Dr Knut Liepe, Nuclear Medicine, GH Kassel, Kassel, Germany | |
| 1150 – 1210 S-49 | SIR-Spheres in HCC Dr Jaroslaw Cwikla, Nuclear Medicine, Faculty of Medical Science, University of Varmia and Masuria Olsztyn Poland | |
| 1210 – 1230 S-50 | Re-188 Lipiodol Therapy for HCC – A New Approach and Perspective from the Rhenium Users' Group Prof Ajit Kumar Padhy, Nuclear Medicine & PET, Singapore General Hospital, Singapore | |
| 1230 – 1250 S-51 | I-131-Lipiodol Therapy in Local Disease Control and Survival in Patients with Advanced Hepatocellular Carcinoma and Metastatic Liver Disease from other Primary Tumors: Our Initial Experience Dr Kumarswamy Kallur, Nuclear Medicine, Healthcare Global Enterprises Pvt Ltd, Bangalore, India | |
| 1250 – 1310 S-52 | Therapy of Colorectal Cancer Tumours with an Agonist DR5 Antibody Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia | |
| 1310 – 1410 | LUNCH / TRADE EXHIBITION | Restaurant Okta, Ground Floor Hotel Levi Panorama |
| 1410 – 1550 | SCIENTIFIC SESSION 17: MISCELLANEOUS/NEW THERAPIES/ FUTURE TRENDS | Auditorium, Ground Floor |
| Session Chairpersons: 1. Dr Chiara Grana, Nuclear Medicine, European Institute of Oncology, Milano, Italy 2. Dr Emerita Barrenechea, Nuclear Medicine, Veterans Memorial Medical Centre, Quezon City, Philippines | | |
| 1410 – 1430 S-53 | Outside the Box: Challenging Cases for Radioimmunotherapy Dr Michael Tombllyn, Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, USA | |
| 1430 – 1450 S-54 | Ancient Features of Personalizing Cancer Treatment; Learning from Radionuclide Therapy in the Era of Targeted Therapies Dr So Won Oh, Nuclear Medicine, Seoul National University Boramae Hospital, Seoul, Korea | |
| 1450 – 1510 S-55 | Quantitative Imaging of Radiotracer Biodistributions Prof Anna Celler, Radiology, UBC, VGH Research Pavilion, Vancouver, Canada | |
| 1510 – 1530 S-56 | Quality of Life (QOL) Assessment in Neuroendocrine Tumor (NET) Patients Prof Irene Virgolini, Nuclear Medicine & PET, Medical University of Innsbruck, Innsbruck, Austria | |
| 1530 – 1550 S-57 | Quality of Life in Oncological patients and Radionuclide Therapy Mr William Claxton, Carcinoid & Neuroendocrine Tumor Society, Singapore | |
| 1550 – 1615 | COFFEE / TEA / TRADE EXHIBITION / TRADE EXHIBITION | |
| 1615 – 1735 | SCIENTIFIC SESSION 18: FINAL SESSION | Auditorium, Ground Floor |
| Session Chairpersons: 1. Prof Andrew Scott, Nuclear Medicine & PET, Ludwig Institute for Cancer Research, Heidelberg, Australia 2. Prof Abdelhamid Elgazzar, Medical Faculty, University of Kuwait, Safat, Kuwait | | |
| 1615 – 1640 S-58 | Radionuclide Therapy: From Radium to Radium Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom | |
| 1640 – 1700 S-59 | Outpatient Therapeutic Oncology Prof Harvey Turner, Nuclear Medicine, Fremantle Hospital, Fremantle, Australia | |

Day 4: Wednesday, 28 November 2012

| | | |
|--|--|--|
| 1700 – 1800 | CLOSING | Auditorium, Ground Floor |
| Awards: Best Oral presentations & Posters | | |
| Impressions from Participants | | |
| Welcome to ICRT 2013 (Cairo, Egypt) Prof Abdelhamid Elgazzar, Local Organising Chairman, ICRT 2013 | | |
| Declaration of Results of WARMTH Elections for The Next Governing Body (2013 – 2014) | | |
| Impressions Prof Richard P Baum, THERANOSTICS Center for Molecular Radiotherapy/Imaging, Zentralklinik Bad Berka, Bad Berka, Germany | | |
| Impressions Prof Alan Perkins, Radiological and Imaging Sciences, Nottingham University Hospital, Nottingham, United Kingdom | | |
| Impressions Prof Kalevi Kairemo, Local Organising Chairman, ICRT 2012 | | |
| Closing Remarks Prof Ajit Kumar Padhy | | |
| 1800 | END OF SCIENTIFIC PROGRAM | |
| 1900 | DINNER: Theme “Blue Dress”. Participants are requested to wear something blue (Any shade of blue) | Restaurant Okta, Ground Floor Hotel Levi Panorama |
| 2300 | END OF DAY 3 | |

Day 5: THURSDAY, 29 NOVEMBER 2012

| | | |
|---|--|--|
| Sight-Seeing Tour & Oenophilous Dinner | | |
| 0730 | Departure from Hotel | |
| 0730 – 1200 | Whole Day Excursion To Rovaniemi: Part I <ul style="list-style-type: none"> ▪ Arctic Circle ▪ Santa Claus Village ▪ Arctic Science Museum | |
| 1200 – 1400 | LUNCH | |
| 1400 – 1800 | Whole Day Excursion To Rovaniemi: Part II <ul style="list-style-type: none"> ▪ Arctic Circle ▪ Santa Claus Village ▪ Arctic Science Museum | |
| 1800 – 2200 | Oenophilous Dinner & Closing | |

Day 6: Friday, 30 November 2012

Departure to respective countries